+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032- Product Image
Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032- Product Image
New

Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 187 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5716358
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Obsessive-Compulsive Disorder Drugs Market is undergoing strategic transformation as evolving therapeutic modalities, supply-chain realignment, and increased demand for precision care reshape both clinical approaches and commercialization strategies.

Market Snapshot: Obsessive-Compulsive Disorder Drugs Market

The Obsessive-Compulsive Disorder Drugs Market grew from USD 1.05 billion in 2025 to USD 1.13 billion in 2026. With a projected CAGR of 8.91%, the market is anticipated to reach USD 1.91 billion by 2032. Analysis indicates that legacy pharmaceutical products, innovative therapeutics, and digital health infrastructure are driving new opportunities and intensifying competition in the treatment landscape.

Scope & Segmentation

  • Drug Classes: Monoamine oxidase inhibitors (MAOIs) like Phenelzine and Tranylcypromine, serotonin-norepinephrine reuptake inhibitors (SNRIs) such as Desvenlafaxine, Duloxetine, Venlafaxine, selective serotonin reuptake inhibitors (SSRIs) including Citalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, and tricyclic antidepressants (TCAs) like Amitriptyline, Clomipramine, and Imipramine.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies, each influencing prescribing, initiation, and long-term patient adherence across various treatment settings.
  • Drug Types: Distinction between branded and generic products, with generics shaping cost-containment and brands focusing on differentiation via clinical data and support programs.
  • Routes of Administration: Predominantly oral therapies for routine management, with parenteral and device-based options reserved for refractory populations.
  • End Users: Clinics, hospitals, and households, each requiring tailored drug access, support, and logistics solutions for both pharmacologic and behavioral interventions.
  • Patient Age Groups: Different protocols for adults and pediatric patients, reflected in dosing, safety monitoring, regulatory strategies, and communication needs.
  • Regions Covered: Americas, Europe Middle East & Africa, and Asia-Pacific, reflecting diverse healthcare ecosystems, regulatory pathways, and market entry drivers.
  • Technologies: Emergence of neuromodulation, glutamatergic agents, digital health platforms, pharmacogenomics, and integrated device-based solutions in differentiated care models.

Key Takeaways

  • Clinical management strategies are evolving to incorporate multi-modal pathways, blending established pharmacotherapy with behavioral therapy and device-based adjuncts to address heterogeneous OCD presentations.
  • Scientific advances in neuromodulation, glutamatergic modulation, and digital therapeutics are enriching the portfolio of options for partial responders and treatment-resistant patients.
  • Payers are pushing rigorous evaluation for value and outcomes, making robust real-world evidence central to market access and competitive positioning for both established and novel therapies.
  • Operational agility, including diversified sourcing, near-shoring, and transparent supplier networks, is increasingly important for mitigating supply chain exposure and maintaining access in the face of tariff volatility.
  • Market segmentation by drug class, type, distribution channel, and patient group is enabling organizations to develop more precise targeting strategies and build branded or generic differentiation.
  • Regional differences in reimbursement, regulatory frameworks, and telepsychiatry adoption are driving the need for localized market access models and flexible go-to-market execution.

Tariff Impact on Market and Supply Chain

Recent trade policy changes and tariff dynamics are reshaping manufacturing, procurement, and pricing structures for obsessive-compulsive disorder therapeutics. Manufacturers and contract organizations are accelerating regional investments and adopting near-shoring to mitigate volatility. These shifts affect lead times and inventory strategies and require tighter coordination among commercial and supply teams to sustain product flow across hospital, online, and retail channels. The increased cost pressures are prompting process optimization initiatives and more selective procurement to maintain market access while controlling total cost of care for payers and providers.

Methodology & Data Sources

This report integrates clinical evidence synthesis, regulatory review, scenario analysis, and in-depth interviews with clinicians, procurement specialists, payers, and senior industry stakeholders. Evidence mapping relied on peer-reviewed literature, guideline statements, device registries, and commercial data, triangulated with qualitative insights to present actionable market intelligence.

Why This Report Matters

  • Enables executive teams to align strategic planning with regional regulatory and access dynamics for obsessive-compulsive disorder drugs.
  • Supports investment, sourcing, and portfolio decisions through granular market segmentation and analysis of emerging competitive models, including digital health and supply chain adaptation.
  • Provides actionable intelligence for navigating evolving payer expectations, operational risks, and new therapeutic delivery paradigms.

Conclusion

Senior decision-makers who leverage up-to-date clinical evidence, robust supply chain strategies, and market-driven segmentation will be best positioned for sustained differentiation across the OCD therapeutics market. Enduring clinical need and evolving care models reward organizations that combine innovation with disciplined commercial execution.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class
8.1. MAOIs
8.1.1. Phenelzine
8.1.2. Tranylcypromine
8.2. SNRIs
8.2.1. Desvenlafaxine
8.2.2. Duloxetine
8.2.3. Venlafaxine
8.3. SSRIs
8.3.1. Citalopram
8.3.2. Fluoxetine
8.3.3. Fluvoxamine
8.3.4. Paroxetine
8.3.5. Sertraline
8.4. TCAs
8.4.1. Amitriptyline
8.4.2. Clomipramine
8.4.3. Imipramine
9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel
9.1. Hospital Pharmacy
9.2. Online Pharmacy
9.3. Retail Pharmacy
10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type
10.1. Brand
10.2. Generic
11. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration
11.1. Oral
11.2. Parenteral
12. Obsessive-Compulsive Disorder Drugs Market, by End User
12.1. Clinics
12.2. Hospitals
12.3. Households
13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group
13.1. Adult
13.2. Pediatric
14. Obsessive-Compulsive Disorder Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Obsessive-Compulsive Disorder Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Obsessive-Compulsive Disorder Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Obsessive-Compulsive Disorder Drugs Market
18. China Obsessive-Compulsive Disorder Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc
19.6. Alembic Pharmaceuticals Ltd
19.7. Amneal Pharmaceuticals Inc
19.8. Apotex Inc
19.9. AstraZeneca PLC
19.10. Aurobindo Pharma Limited
19.11. Biogen Inc
19.12. Dr Reddy's Laboratories Ltd
19.13. Eli Lilly and Company
19.14. GlaxoSmithKline plc
19.15. H Lundbeck A/S
19.16. Johnson & Johnson
19.17. Lupin Pharmaceuticals Inc
19.18. Mallinckrodt plc
19.19. Merck & Co Inc
19.20. Novartis AG
19.21. Omeros Corporation
19.22. Otsuka Pharmaceutical Co Ltd
19.23. Pfizer Inc
19.24. Sanofi
19.25. Sun Pharmaceutical Industries Ltd
19.26. Teva Pharmaceutical Industries Ltd
19.27. Torrent Pharmaceuticals Ltd
19.28. Viatris Inc
19.29. Zydus Pharmaceuticals Inc
List of Figures
FIGURE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 152. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 166. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 169. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 170. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 172. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 174. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 192. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 193. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 197. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 202. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 203. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 204. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 205. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 206. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 208. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 222. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 225. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 226. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 227. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 228. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 230. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 231. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 236. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 237. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 238. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 239. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 241. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 244. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 246. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 247. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 248. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 249. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 250. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 252. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 267. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 269. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
TABLE 270. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 271. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
TABLE 272. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 273. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 274. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 275. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 277. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Obsessive-Compulsive Disorder Drugs market report include:
  • AbbVie Inc
  • Alembic Pharmaceuticals Ltd
  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H Lundbeck A/S
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc
  • Mallinckrodt plc
  • Merck & Co Inc
  • Novartis AG
  • Omeros Corporation
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Viatris Inc
  • Zydus Pharmaceuticals Inc

Table Information

Report AttributeDetails
No. of Pages187
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.13 Billion
Forecasted Market Value ( USD ) by 2032 $ 1.91 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Obsessive-Compulsive Disorder Market Report 2025 - Product Image

Obsessive-Compulsive Disorder Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Obsessive-Compulsive Disorder Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Obsessive-Compulsive Disorder Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Obsessive-Compulsive Disorder Drugs Market - Global Strategic Business Report - Product Image

Obsessive-Compulsive Disorder Drugs Market - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Obsessive-Compulsive Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Obsessive-Compulsive Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Obsessive Compulsive Disorder- Pipeline Insight, 2025 - Product Image

Obsessive Compulsive Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Market

Obsessive Compulsive Disorder (OCD) is a mental disorder characterized by intrusive thoughts that produce anxiety, and by repetitive behaviors aimed at reducing that anxiety. OCD is treated with a combination of psychotherapy and medication. Drugs used to treat OCD include selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors (MAOIs). SSRIs are the most commonly prescribed medications for OCD, as they are generally well-tolerated and have fewer side effects than other medications. The OCD drug market is highly competitive, with a number of major pharmaceutical companies offering products. These include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Other companies, such as Lundbeck, Otsuka, and Sunovion, also offer products for the treatment of OCD. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.